The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has been the most established biosimilar treatment in the Canadian ...

The UK health service has well over a decade’s experience of dealing with biosimilars, but the NHS acknowledges that it has yet to make the most of these drugs. That was certainly one of the ...

March 25, 2025 at 4 PM - Martin Krzywinski Creative Workshop Hosted by Martin Krzywinski in Rehki 112 Working on an Art in Silico submission and would like an extra set of expert eyes? Working on a ...

South Korean biopharmaceutical company Celltrion announced Thursday that it has launched Steqeyma (ustekinumab), a biosimilar treatment for autoimmune diseases, in the US market. Steqeyma ...

JERSEY CITY, N.J., March 13, 2025 /PRNewswire/ -- Celltrion today announced the U.S. launch of STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab), following approval by the U.S.

TORONTO — Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new brand name Remdantry TM starting April 1, ...

JERSEY CITY, N.J., March 12, 2025 /PRNewswire/ -- Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following approval by the U ...

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...

Although advanced biologics offer hope, their high prices add to the distress. Fortunately, now more affordable biosimilars- nearly identical to biologics – can substantially reduce costs. Therapeutic ...